What is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a pyridine dinucleotide coenzyme described in the literature as present in essentially all living cells. It is reported to participate in redox chemistry by cycling between its oxidized form (NAD+) and reduced form (NADH), and is characterized as a central cofactor in energy-related metabolic pathways. Reviews also describe NAD+ as a substrate consumed by several enzyme families rather than acting solely as a redox carrier.
In the research literature, NAD+ is studied as a small-molecule reference compound for in-vitro biochemistry and as a metabolite of interest in animal-model work. VANTA supplies NAD+ strictly as a reference-grade material for laboratory research use only. Nothing on this page describes use in humans or animals outside controlled experimental settings.
Studied mechanisms
Published reviews describe NAD+ as a cofactor and as a substrate for NAD+-consuming enzyme families, including sirtuins, poly(ADP-ribose) polymerases (PARPs), and the glycohydrolase CD38. In these mechanistic frameworks, intracellular NAD+ availability is discussed as a factor that researchers have associated with the activity of these enzymes in experimental systems.
One line of preclinical work has examined CD38 as a major NAD+-consuming enzyme; investigators reported that CD38 inhibition was associated with changes in tissue NAD+ levels in aged mice (Tarragó et al., Cell Metabolism, 2018). Mechanistic reviews further situate NAD+ within pathways studied for DNA-repair signaling, mitochondrial function, and metabolic regulation. These descriptions reflect what researchers have observed in laboratory models and are not statements about any effect in people.
Research models and findings (hedged)
NAD+ and its precursors have been examined across in-vitro assays and rodent models. In one widely cited study, repletion of NAD+ via a precursor was associated with changes in mitochondrial and stem-cell measures and with lifespan readouts in mice (Zhang et al., Science, 2016). Other preclinical work has explored NAD+-related pathways in models of liver and metabolic stress.
Several systematic reviews summarize this body of preclinical rodent work and consistently note that findings observed in animal and in-vitro models have shown limited and inconsistent translation when examined in human clinical settings. Researchers have emphasized this preclinical-to-clinical gap as an open question. VANTA presents these citations so investigators can review the primary literature directly; we make no efficacy, therapeutic, or health claims of any kind.
Why characterization matters in NAD+ research
Because NAD+ is studied as a reference metabolite, experimental reproducibility depends on knowing exactly what is in the vial. Identity ambiguity (for example, confusion between NAD+, NADH, or precursor compounds such as NMN and NR) and the presence of degradation products or residual synthesis impurities can confound assay results. The literature treats NAD+ as part of a tightly interconnected metabolite network, so analytical certainty about the test article is a prerequisite for interpretable data.
For this reason, researchers typically require documented identity and purity before incorporating any reference compound into an experimental workflow. This is a quality-control consideration for laboratory work, not a statement about any biological activity.
How VANTA verifies it
Every VANTA NAD+ lot is characterized before release. We use high-performance liquid chromatography (HPLC) to assess chromatographic purity and mass spectrometry to confirm molecular identity against the expected mass of the compound. These orthogonal methods are intended to distinguish the target material from related metabolites and from degradation products.
Each batch ships with a per-batch Certificate of Analysis (COA) documenting the measured purity and identity results for that specific lot. This per-lot documentation is provided so laboratory researchers can record provenance and analytical specifications in their own records. VANTA materials are sold for research use only and are not intended for human or veterinary use, diagnostic procedures, or any consumption.
References
- 1.Zhang et al., Science 2016 - NAD+ repletion, mitochondrial/stem-cell function and lifespan in mice (preclinical)
- 2.Tarragó et al., Cell Metabolism 2018 - CD38 inhibition and tissue NAD+ decline in aged mice (mechanism/preclinical)
- 3.Systematic review - NAD+ precursors for cognitive endpoints in preclinical rodent models
- 4.Review - therapeutic perspective of NAD+ precursors in age-related disease literature
- 5.Review - NAD+ precursors in human ageing: clinical evidence and the preclinical-to-clinical gap